Open Access
mAbs, volume 12, issue 1
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
Marco Tuccori
1, 2
,
Sara Ferraro
2
,
Irma Convertino
2
,
Emiliano Cappello
2
,
Giulia Valdiserra
2
,
Corrado Blandizzi
1, 2
,
Fabrizio Maggi
3
,
Daniele Focosi
4
3
Division of Microbiology, Varese University Hospital, Varese, Italy
|
Publication type: Journal Article
Publication date: 2020-01-01
PubMed ID:
33319649
Immunology
Immunology and Allergy
Found
Found
Top-30
Journals
|
1
2
3
4
5
6
|
|
|
Vaccines
6 publications, 4.72%
|
|
|
Viruses
5 publications, 3.94%
|
|
|
Scientific Reports
5 publications, 3.94%
|
|
|
Nature Communications
3 publications, 2.36%
|
|
|
Signal Transduction and Targeted Therapy
3 publications, 2.36%
|
|
|
mAbs
3 publications, 2.36%
|
|
|
Immunotherapy
2 publications, 1.57%
|
|
|
PLoS ONE
2 publications, 1.57%
|
|
|
Frontiers in Immunology
2 publications, 1.57%
|
|
|
Journal of Biomedical Science
2 publications, 1.57%
|
|
|
Computational and Structural Biotechnology Journal
2 publications, 1.57%
|
|
|
International Immunopharmacology
2 publications, 1.57%
|
|
|
The Lancet Infectious Diseases
2 publications, 1.57%
|
|
|
Expert Opinion on Drug Discovery
2 publications, 1.57%
|
|
|
Science advances
2 publications, 1.57%
|
|
|
Science Translational Medicine
1 publication, 0.79%
|
|
|
AIDS Research and Human Retroviruses
1 publication, 0.79%
|
|
|
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
1 publication, 0.79%
|
|
|
Biochemical Society Transactions
1 publication, 0.79%
|
|
|
Molecular Medicine Reports
1 publication, 0.79%
|
|
|
Clinical Nurse Specialist
1 publication, 0.79%
|
|
|
Infectious Diseases in Clinical Practice
1 publication, 0.79%
|
|
|
World Journal of Virology
1 publication, 0.79%
|
|
|
Internal Medicine
1 publication, 0.79%
|
|
|
Inquiry (United States)
1 publication, 0.79%
|
|
|
Life
1 publication, 0.79%
|
|
|
Antioxidants
1 publication, 0.79%
|
|
|
International Journal of Molecular Sciences
1 publication, 0.79%
|
|
|
Pathogens
1 publication, 0.79%
|
|
|
1
2
3
4
5
6
|
Publishers
|
5
10
15
20
25
|
|
|
Elsevier
25 publications, 19.69%
|
|
|
Springer Nature
23 publications, 18.11%
|
|
|
MDPI
21 publications, 16.54%
|
|
|
Cold Spring Harbor Laboratory
13 publications, 10.24%
|
|
|
Taylor & Francis
9 publications, 7.09%
|
|
|
Wiley
6 publications, 4.72%
|
|
|
American Association for the Advancement of Science (AAAS)
4 publications, 3.15%
|
|
|
Frontiers Media S.A.
4 publications, 3.15%
|
|
|
Public Library of Science (PLoS)
3 publications, 2.36%
|
|
|
American Society for Microbiology
3 publications, 2.36%
|
|
|
Mary Ann Liebert
2 publications, 1.57%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 1.57%
|
|
|
Portland Press
1 publication, 0.79%
|
|
|
Spandidos Publications
1 publication, 0.79%
|
|
|
Baishideng Publishing Group
1 publication, 0.79%
|
|
|
Japanese Society of Internal Medicine
1 publication, 0.79%
|
|
|
SAGE
1 publication, 0.79%
|
|
|
International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
1 publication, 0.79%
|
|
|
Oxford University Press
1 publication, 0.79%
|
|
|
Hindawi Limited
1 publication, 0.79%
|
|
|
Acta Naturae Ltd
1 publication, 0.79%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.79%
|
|
|
Pharmaceutical Society of Japan
1 publication, 0.79%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.79%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Tuccori M. et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline // mAbs. 2020. Vol. 12. No. 1.
GOST all authors (up to 50)
Copy
Tuccori M., Ferraro S., Convertino I., Cappello E., Valdiserra G., Blandizzi C., Maggi F., Focosi D. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline // mAbs. 2020. Vol. 12. No. 1.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1080/19420862.2020.1854149
UR - https://www.tandfonline.com/doi/full/10.1080/19420862.2020.1854149
TI - Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
T2 - mAbs
AU - Tuccori, Marco
AU - Ferraro, Sara
AU - Convertino, Irma
AU - Cappello, Emiliano
AU - Valdiserra, Giulia
AU - Blandizzi, Corrado
AU - Maggi, Fabrizio
AU - Focosi, Daniele
PY - 2020
DA - 2020/01/01
PB - Taylor & Francis
IS - 1
VL - 12
PMID - 33319649
SN - 1942-0862
SN - 1942-0870
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_Tuccori,
author = {Marco Tuccori and Sara Ferraro and Irma Convertino and Emiliano Cappello and Giulia Valdiserra and Corrado Blandizzi and Fabrizio Maggi and Daniele Focosi},
title = {Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline},
journal = {mAbs},
year = {2020},
volume = {12},
publisher = {Taylor & Francis},
month = {jan},
url = {https://www.tandfonline.com/doi/full/10.1080/19420862.2020.1854149},
number = {1},
doi = {10.1080/19420862.2020.1854149}
}